IN10018: Clinical Trials

7 trials of IN10018, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 active not recruiting, 1 recruiting, 1 withdrawn. 7 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Active not recruiting 5, Recruiting 1, Withdrawn 1
Phase 15Active not recruiting 4, Withdrawn 1

Follow IN10018: new trials by email Literature Review of IN10018 trials Research Report on IN10018

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IN10018 Combination Therapy in Previously-treated Solid Tumors
IN10018, Nab-paclitaxel, Tislelizumab - Solid Tumor
Phase 1 / Phase 2WithdrawnInxMed (Shanghai) Co., Ltd.2025-08-132026-03-27
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
IN10018, Nab-paclitaxel, Cadonilimab - Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma
Phase 2RecruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology252025-02-172026-01-13
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
IN10018, Tislelizumab, Carboplatin - Small Cell Lung Cancer Extensive Stage
Phase 1 / Phase 2Active not recruitingInxMed (Shanghai) Co., Ltd.1202023-10-302026-11-12
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
IN10018, Furmonertinib - NSCLC
Phase 1 / Phase 2Active not recruitingInxMed (Shanghai) Co., Ltd.1102023-07-132026-11-12
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
IN10018, Albumin-Bound Paclitaxel, Gemcitabine - Pancreatic Cancer
Phase 1 / Phase 2Active not recruitingInxMed (Shanghai) Co., Ltd.702022-12-082026-11-12
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
D-1553, IN10018 - Solid Tumor
Phase 1 / Phase 2Active not recruitingInventisBio Co., Ltd922022-10-122026-07-17
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent
Phase 2Active not recruitingInxMed (Shanghai) Co., Ltd.1682022-09-062026-11-12

Conditions studied

Pancreatic Neoplasms (1)

Sponsors

InxMed (Shanghai) Co., Ltd. (5)  ·  InventisBio Co., Ltd (1)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)

Countries

China (6)

Top investigators

Caicun Zhou (1)  ·  Jifeng Feng (1)  ·  Jun Zhao (1)  ·  Lingying WU (1)  ·  Liwei Wang (1)  ·  Peng Wu, Ph.D (1)  ·  Zhengbo Song (1)

Results publications

PMID 42413526, PMID 42636835